Esperion Therapeutics to Host Conference Call on September 3, 2013 to Announce Top-line Results from a Phase 2 Clinical Study of ETC-1002 as an Add-On to Statin Therapy in Patients with Hypercholesterolemia

Business Wire

PLYMOUTH, Mich.--(BUSINESS WIRE)--

Esperion Therapeutics, Inc. (ESPR), a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia, today announced that it will host a conference call and webcast on Tuesday, September 3, 2013 at 8:30 a.m. Eastern Time (ET) to present top-line results from a Phase 2a clinical study of its lead product candidate, ETC-1002, as an add-on to statin therapy in patients with hypercholesterolemia.

The live event will be accessible on the Esperion website beginning at 8:30 a.m. at www.esperion.com, under the Investors section, or by calling (877) 312-7508 (domestic) or (253) 237-1184 (international). The access code is 28976349. A replay of the event will be available beginning at approximately 10:00 a.m. ET on September 3, 2013 from the Esperion website or by calling (855) 859-2056 (domestic) or (404) 537-3406 (international), using access code 28976349. The replay will be available through September 17, 2013.

About Esperion Therapeutics

Esperion Therapeutics, Inc. is a biopharmaceutical company focused on the research, development and commercialization of therapies for the treatment of patients with elevated levels of LDL-C and other cardiometabolic risk factors. ETC-1002, Esperion's lead product candidate, is a unique, first-in-class, orally available, once-daily small molecule designed to lower levels of LDL-C and to avoid side effects associated with existing LDL-C lowering therapies. ETC-1002 is targeted for statin intolerant patients with elevated levels of LDL-C. Esperion has completed seven clinical studies to date, including four Phase 2a studies, and expects to initiate a robust Phase 2b clinical program in the fourth quarter of 2013. For more information, please visit www.esperion.com.

Forward Looking Statements

This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding the anticipated timing of Esperion’s Phase 2b clinical program. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements involve risks and uncertainties that could cause Esperion's actual results to differ significantly from those projected, including, without limitation, the risk that unanticipated developments could interfere with the development (and commercialization) of ETC-1002, as well as other risks detailed in Esperion's filings with the Securities and Exchange Commission, including our Quarterly Report on Form 10-Q filed with Securities and Exchange Commission on August 12, 2013. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this release. Esperion disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release, other than to the extent required by law.

Contact:
BrewLife
Denise Powell
510-703-9491
dpowell@brewlife.com
View Comments